Research at the Florida State University College of Medicine has identified a potential low-cost method for predicting if a person is at risk of developing dementia.
Novel Drug Better Than Wegovy? New Endocrine Society Prez; Knockoff Tirzepatide Woes
In a phase I trial, investigational amycretin led to greater weight loss compared with historical benchmarks set by semaglutide (Wegovy), according to drugmaker Novo Nordisk.